① Gene therapy developer VoyagerTherapeutics has reached a strategic cooperation and licensing agreement with Novartis Pharmaceuticals subsidiaries to advance novel gene therapies for Huntington's disease and spinal muscular atrophy. ② The agency expects the global gene editing market to reach US$36.61 billion by 2030, with a compound annual growth rate of 22.3%.
Gene therapy developer VoyagerTherapeutics has reached a strategic cooperation and licensing agreement with Novartis Pharmaceuticals subsidiaries to advance novel gene therapies for Huntington's disease (HD) and spinal muscular atrophy (SMA). Under the agreement, VoyagerTherapeutics will provide Novartis with an exclusive license for its TRACER capsid development platform, as well as other intellectual property rights for Huntington's disease (HD) and spinal muscular atrophy (SMA). The two sides will cooperate to advance drug candidates for Huntington's disease (HD) and spinal muscular atrophy (SMA) and preclinical gene therapy.
Gene therapy can treat the root causes of diseases, and can even achieve curative effects, and is rapidly developing and can be used in various medical fields, and may open a new chapter in the field of medicine. According to Allied Market Research and Global Market Research, the global gene editing market is expected to reach US$36.61 billion by 2030, with a compound annual growth rate of 22.3%.
According to the Finance Federation's theme library, among the relevant listed companies:
With big data from the Chinese population's disease-causing genes information base as the core, Berry Genes has finally built an ecosystem covering the four major sectors of production, learning, research, and capital through technical methods such as cloud computing, genetic sequencing, gene editing, and artificial intelligence.
Shuanglu Pharmaceutical invests in ATGC of the United States and is strengthening cooperation with ATGC in gene editing and other series of technologies related to the production of genetically modified rabbits.